Core Insights - Medtronic announced three significant milestones in the U.S. aimed at expanding access and flexibility for individuals with type 1 and insulin-requiring type 2 diabetes, including Medicare access for the MiniMed™ 780G system with the Instinct sensor, FDA clearance for its use with ultra rapid-acting insulins, and clearance for use with insulin-requiring type 2 diabetes [1][2][6]. Group 1: Medicare Access - Medicare beneficiaries can now access the MiniMed™ 780G system paired with the Instinct sensor, which is small, thin, and can be worn discreetly for up to 15 days [3][5]. - This milestone enhances sensor choice for Medicare users, who also have access to the Simplera Sync™ and Guardian™ 4 sensors [3]. Group 2: FDA Clearances - The FDA has cleared the MiniMed™ 780G system for use with ultra rapid-acting insulins, such as Fiasp and Lyumjev, providing more flexibility and personalization in diabetes therapy [6]. - The system's Meal Detection™ technology allows for better management of mealtime insulin delivery, accommodating missed or delayed doses [6]. Group 3: Benefits of the MiniMed™ 780G System - The MiniMed™ 780G system automates insulin delivery every five minutes, which helps maintain stable glucose control and reduces the burden of daily decision-making for users [4][9]. - The integration of the Instinct sensor with the MiniMed™ 780G system is expected to improve the daily management experience for individuals with type 2 diabetes [10].

Core Insights - A new retrospective analysis published in Diabetes Care indicates that users of the MiniMed™ 780G system can achieve American Diabetes Association (ADA) recommended goals for time-in-range (TIR) even on days when mealtime boluses are missed, with a reported TIR of 76.3% on such days when using SmartGuard™ technology with optimal settings [1][4][6] Group 1: Study Findings - The study analyzed real-world CareLink™ user data from 369,467 individuals using the MiniMed™ 780G insulin pump, focusing on 54,553 users who experienced at least 10 days without bolusing between January 2, 2020, and March 31, 2025 [4] - Users employing recommended optimal settings achieved a TIR of 76.3%, compared to 69.3% for those using non-recommended settings, with a mean sensor glucose of 149 mg/dL versus 160 mg/dL [6] - More than 61% of users with recommended optimal settings met all three ADA recommended glycemic targets on missed bolus days, compared to 36.6% of users with other settings [6] Group 2: Implications for Diabetes Management - The findings underscore the advanced capabilities of the MiniMed™ 780G system, which adjusts insulin delivery every five minutes based on sensor readings, providing support when boluses are missed or carbohydrates are underestimated [3][4] - The study highlights the importance of optimized settings in diabetes management, particularly for users who may occasionally miss boluses, thereby reducing the overall burden of diabetes care [2][4] Group 3: Company Overview - Medtronic Diabetes aims to make diabetes management more predictable through advanced technology, including next-generation sensors and intelligent dosing systems [8] - The company has been a pioneer in diabetes technology for over 40 years, focusing on customer experience and innovative solutions to improve health outcomes [9]

Core Insights - Medtronic plc's board of directors approved a cash dividend of $0.71 per ordinary share for the third quarter of fiscal year 2026, consistent with a previous increase announced in May 2025 [1] - The company has a strong history of dividend payments, having increased its annual dividend for 48 consecutive years, and is part of the S&P 500 Dividend Aristocrats index [1] - The dividend will be payable on January 16, 2026, to shareholders of record as of December 26, 2025 [1] Company Overview - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [2] - The company's mission is to alleviate pain, restore health, and extend life, supported by a workforce of over 95,000 employees across more than 150 countries [2] - Medtronic's technologies and therapies address 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems [2]

Core Insights - Medtronic has launched the MiniMed™ 780G system integrated with Abbott's Instinct sensor in the U.S., marking a significant advancement in diabetes management technology [1][2][3] Product Launch - The MiniMed™ 780G system is now commercially available following FDA clearance, allowing for integration with the Instinct sensor [1][2] - The Instinct sensor is noted for being the world's smallest and thinnest continuous glucose monitor (CGM), with a wear time of up to 15 days [3][6] Technology Features - The MiniMed™ 780G system automates insulin adjustments every five minutes based on real-time glucose readings, which helps users manage diabetes more effectively [3][6] - The combination of the Instinct sensor and the MiniMed™ 780G system has received positive feedback from early users, indicating improved time in glucose range for patients [4][5] Market Positioning - The launch of the Instinct sensor expands Medtronic's sensor portfolio, which includes the recently launched Simplera Sync™ sensor and the Guardian™ 4 sensor, enhancing the company's offerings in diabetes care [4][5] - Medtronic aims to provide a personalized diabetes management experience, allowing users to choose solutions that best fit their lifestyles [5][7] Company Mission - Medtronic's mission is to make diabetes management more predictable and to improve the quality of life for individuals living with diabetes through advanced technology and support [7][8]

Core Insights - Medtronic plc reported a strong Q2 FY26 with revenue of $9.0 billion, reflecting a 6.6% increase as reported and 5.5% organic growth, exceeding guidance midpoint by 75 basis points [1] - The company raised its FY26 guidance to 5.5% organic revenue growth and adjusted EPS of $5.62-$5.66 [1] - Cardiac Ablation Solutions experienced significant growth of 71%, with a remarkable 128% increase in the U.S., driven by the pulsed field ablation (PFA) portfolio [1] Financial Performance - GAAP diluted EPS increased by 8% to $1.07, while non-GAAP diluted EPS also rose by 8% to $1.36, both above guidance [1] - The cardiovascular segment achieved its strongest revenue growth in over a decade, excluding pandemic effects [1] Product Developments - The company received broad favorable National Coverage Determination (NCD) from U.S. Centers for Medicare & Medicaid Services (CMS) for the Symplicity™ procedure, targeting an addressable market of 18 million people with uncontrolled hypertension [1] - Medtronic secured U.S. FDA approval for the Altaviva™ device, aimed at treating urge urinary incontinence, which affects over 16 million people in the U.S. [1] - The Hugo™ robotic-assisted surgery system met safety and effectiveness endpoints in the Enable Hernia Repair study and initiated the Embrace Gynecology US pivotal study [1] - The U.S. FDA cleared the MiniMed™ 780G system for integration with the Instinct sensor and approved its use in Type 2 diabetes [1]

Core Insights - Medtronic plc has received CE Mark approval in Europe to expand the indications for the MiniMed™ 780G system, allowing its use for individuals aged 2 years and older, during pregnancy, and for those with type 2 diabetes [1] Group 1: Expanded Indications - The MiniMed™ 780G system is now indicated for children aged 2-6 years with type 1 diabetes, showing a 0.6% reduction in HbA1C and a 9.9% increase in time in range when used in auto mode compared to manual mode [2] - The system has been recognized as a standard of care for children with type 1 diabetes across Europe, with guidelines from NICE and the German Diabetes Association recommending its use [3][4] Group 2: Pregnancy Management - The MiniMed™ 780G system offers significant benefits for managing type 1 diabetes during pregnancy, achieving an average Pregnancy Time in Range (TIRp) of 66.5%, which is an improvement over traditional insulin therapy [6] - Clinical guidelines emphasize the importance of tighter glucose control during pregnancy, with the MiniMed™ 780G system providing better overnight glucose control and higher treatment satisfaction among expectant mothers [5][6] Group 3: Type 2 Diabetes Indication - The MiniMed™ 780G system is now also approved for individuals with type 2 diabetes, demonstrating a 0.7% reduction in HbA1c and an increase in time in range to 80% in a pivotal trial [7] - Real-world data from 26,427 users with type 2 diabetes showed good glycemic control, exceeding the international consensus of 70% time in range [7] Group 4: Future Developments - Medtronic is working with U.S. regulatory authorities to expand the use of the MiniMed™ 780G system for individuals with type 2 diabetes, with ongoing clinical trials for children aged 2-6 years [8]

Core Insights - Medtronic plc announced the name "MiniMed" for its planned new Diabetes Company, honoring its legacy and 40-year history in diabetes care [1] - The company aims to enhance diabetes management through innovative technology, making it more predictable and less burdensome for patients [1][2] - The separation of the Diabetes business is targeted for completion within 18 months, subject to legal and customary conditions [3] Company Overview - Medtronic is a global leader in healthcare technology, focusing on transforming diabetes care [1] - The Diabetes business employs over 8,000 individuals dedicated to innovation and improving health outcomes for diabetes patients [2] Historical Context - MiniMed was originally founded in 1983 by Alfred E. Mann, introducing groundbreaking innovations in diabetes care [1] - The name change reflects the company's commitment to its roots and the trust built over decades [1] Future Plans - The separation will involve capital markets transactions, potentially including a spin-off or split-off of the remaining shareholding in MiniMed [5] - The company is committed to fulfilling its mission of making diabetes management more stable and predictable [1][2]

Core Insights - Medtronic has received FDA approval for the Simplera Sync™ sensor, enhancing the MiniMed™ 780G system's capabilities in the U.S. market [1][3] - The Simplera Sync™ sensor is a disposable, all-in-one device that eliminates the need for fingersticks and simplifies the insertion process, providing greater flexibility for users [2][6] - The MiniMed™ 780G system features an adaptive algorithm that adjusts glucose levels every 5 minutes, utilizing Meal Detection™ technology to optimize insulin delivery [2][3] Product Features - The Simplera Sync™ sensor is designed to work seamlessly with the MiniMed™ 780G system, which can now utilize both the Guardian™ 4 sensor and the new Simplera Sync™ sensor [1][3] - The system allows for flexible glucose targets as low as 100 mg/dL and has shown real-world data indicating users achieve over 70% time in range when using optimal settings [2][6] - The MiniMed™ 780G system is the only one that can be paired with an infusion set lasting up to 7 days, significantly reducing the frequency of injections [2][6] Company Commitment - Medtronic is dedicated to innovating diabetes management technologies to improve the quality of life for individuals living with diabetes [3][4] - The company plans a limited launch of the Simplera Sync™ sensor in the U.S. in fall 2025, further expanding its CGM options [3][4] - Medtronic has a long history of pioneering diabetes technology and aims to continue leading in this field through advanced sensors and intelligent dosing systems [4][5]